A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Crohn's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 2 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Janssen Research & Development, LLC
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Cedars Sinai Medical Center · Los Angeles, CA
Georgia · 2
- Children's Center for Digestive Health Care · Atlanta, GA
- Emory University · Atlanta, GA
Massachusetts · 1
- Boston Childrens Hospital · Boston, MA
New Jersey · 1
- Goryeb Children's Hospital · Morristown, NJ
New York · 2
- Icahn School of Medicine at Mount Sinai · New York, NY
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center · New York, NY
Pennsylvania · 1
- Children's Hospital of Philadelphia · Philadelphia, PA
Texas · 1
- Cook Childrens Medical Center · Fort Worth, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.